Literature DB >> 24065311

Insulin sensitivity in normocalcaemic primary hyperparathyroidism.

F Tassone1, M Maccario, L Gianotti, C Baffoni, M Pellegrino, S Cassibba, F Cesario, G Magro, G Borretta.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24065311     DOI： 10.1007/s12020-013-0059-z

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  10 in total

1.  Glucose intolerance and primary hyperparathyroidism: an unresolved relationship.

Authors:  Mishaela R Rubin; Shonni J Silverberg
Journal:  Endocrine       Date:  2012-10       Impact factor: 3.633

2.  Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans.

Authors:  A Katz; S S Nambi; K Mather; A D Baron; D A Follmann; G Sullivan; M J Quon
Journal:  J Clin Endocrinol Metab       Date:  2000-07       Impact factor: 5.958

3.  Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate.

Authors:  Andrew S Levey; Josef Coresh; Tom Greene; Lesley A Stevens; Yaping Lucy Zhang; Stephen Hendriksen; John W Kusek; Frederick Van Lente
Journal:  Ann Intern Med       Date:  2006-08-15       Impact factor: 25.391

4.  Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.

Authors:  M Matsuda; R A DeFronzo
Journal:  Diabetes Care       Date:  1999-09       Impact factor: 19.112

5.  Investigation of insulin resistance in patients with normocalcemic primary hyperparathyroidism.

Authors:  Ilkay Cakir; Kursad Unluhizarci; Fatih Tanriverdi; Gulsah Elbuken; Zuleyha Karaca; Fahrettin Kelestimur
Journal:  Endocrine       Date:  2012-02-12       Impact factor: 3.633

6.  Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion.

Authors:  D I Phillips; P M Clark; C N Hales; C Osmond
Journal:  Diabet Med       Date:  1994-04       Impact factor: 4.359

7.  Insulin resistance is not coupled with defective insulin secretion in primary hyperparathyroidism.

Authors:  F Tassone; M Procopio; L Gianotti; G Visconti; A Pia; M Terzolo; G Borretta
Journal:  Diabet Med       Date:  2009-10       Impact factor: 4.359

Review 8.  Derangement of glucose metabolism in hyperparathyroidism.

Authors:  M Procopio; G Borretta
Journal:  J Endocrinol Invest       Date:  2003-11       Impact factor: 4.256

Review 9.  Primary hyperparathyroidism.

Authors:  John P Bilezikian
Journal:  Endocr Pract       Date:  2012 Sep-Oct       Impact factor: 3.443

10.  Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype.

Authors:  H Lowe; D J McMahon; M R Rubin; J P Bilezikian; S J Silverberg
Journal:  J Clin Endocrinol Metab       Date:  2007-05-29       Impact factor: 5.958
  10 in total
  4 in total

1.  Investigation of glucose intolerance in patients with normocalcemic primary hyperparathyroidism: 4-year follow-up.

Authors:  Halit Diri; Kursad Unluhizarci; Fahrettin Kelestimur
Journal:  Endocrine       Date:  2014-04-11       Impact factor: 3.633

2.  Cardiovascular risk and metabolic syndrome in primary hyperparathyroidism and their correlation to different clinical forms.

Authors:  M Procopio; M Barale; S Bertaina; S Sigrist; R Mazzetti; M Loiacono; G Mengozzi; E Ghigo; M Maccario
Journal:  Endocrine       Date:  2013-11-28       Impact factor: 3.633

3.  The influence of parathyroidectomy on cardiometabolic risk factors in patients with primary hyperparathyroidism: a systematic review and meta-analysis.

Authors:  Maryam Yavari; Awat Feizi; Fahimeh Haghighatdoost; Azin Ghaffari; Hassan Rezvanian
Journal:  Endocrine       Date:  2020-10-15       Impact factor: 3.633

4.  Parathyroidectomy improves cardiovascular risk factors in normocalcemic and hypercalcemic primary hyperparathyroidism.

Authors:  Selvihan Beysel; Mustafa Caliskan; Muhammed Kizilgul; Mahmut Apaydin; Seyfullah Kan; Mustafa Ozbek; Erman Cakal
Journal:  BMC Cardiovasc Disord       Date:  2019-05-08       Impact factor: 2.298
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.